concept

MICROGLIAL ACTIVATION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MICROGLIAL ACTIVATION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

417Connections

2Hypotheses

6Analyses

50Outgoing

50Incoming

0Experiments

8Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info

Name	MICROGLIAL ACTIVATION
Key Genes/Proteins	AIF1, Alpha-Synuclein, ALPHA-SYNUCLEIN, ALZHEIMER, AMYLOID, AMYLOID-BETA
Related Diseases	aging, ALS, Alzheimer Disease, Alzheimer'S Disease, ALZHEIMER'S DISEASE

Pathway Diagram

graph TD
    MICROGLIAL_ACTIVATION["MICROGLIAL ACTIVATION"]
    style MICROGLIAL_ACTIVATION fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    MICROGLIAL_ACTIVATION -->|"contributes to"| Neuromyelitis_Optica_Spectrum_["Neuromyelitis Optica Spectrum Disorders"]
    MICROGLIAL_ACTIVATION -->|"causes"| Inflammatory_Response["Inflammatory Response"]
    MICROGLIAL_ACTIVATION -->|"contributes to"| Neuroinflammation["Neuroinflammation"]
    MICROGLIAL_ACTIVATION -->|"contributes to"| Parkinson_s_Disease["Parkinson's Disease"]
    MICROGLIAL_ACTIVATION -->|"upregulates"| TREM2([TREM2])
    MICROGLIAL_ACTIVATION -->|"upregulates"| APOE([APOE])
    MICROGLIAL_ACTIVATION -->|"contributes to"| Ischemic_Stroke["Ischemic Stroke"]
    MICROGLIAL_ACTIVATION -->|"contributes to"| Tau_Pathology(Tau Pathology)
    MICROGLIAL_ACTIVATION -->|"contributes to"| Behavioral_Impairments(Behavioral Impairments)
    Amyloid_Beta["Amyloid Beta"] -->|"activates"| MICROGLIAL_ACTIVATION
    CKLF([CKLF]) -->|"causes"| MICROGLIAL_ACTIVATION
    Mitophagy["Mitophagy"] -->|"involved_in"| MICROGLIAL_ACTIVATION
    sTREM2["sTREM2"] -.->|"biomarker for"| MICROGLIAL_ACTIVATION
    NRF2([NRF2]) -->|"regulates"| MICROGLIAL_ACTIVATION
    defective_mitophagy(defective mitophagy) -->|"causes"| MICROGLIAL_ACTIVATION
    CKLF1([CKLF1]) -->|"causes"| MICROGLIAL_ACTIVATION
    Alpha_Synuclein_Aggregates["Alpha-Synuclein Aggregates"] -->|"causes"| MICROGLIAL_ACTIVATION
    APOE -->|"activates"| MICROGLIAL_ACTIVATION

Outgoing (132)

Target	Relation	Type	Str
Neurodegeneration	contributes_to	disease	0.92
Neuromyelitis Optica Spectrum Disorders	contributes_to	disease	0.91
Nf-Κb/Nlrp3 Inflammasome Signaling	involved_in	pathway	0.90
Neuroinflammation	contributes_to	process	0.90
Synaptic Elimination	mediates	process	0.90
White Matter Injury	causes	disease	0.90
Pro-inflammatory cytokine release	causes	process	0.90
Inflammatory Response	causes	process	0.90
A1 astrocyte conversion	drives	process	0.90
Neuroinflammation	involved_in	process	0.88
Tau-Associated Neurodegeneration	mediates	phenotype	0.85
cerebral ischemia-reperfusion injury	promotes	disease	0.85
NLRP3 Inflammasome	contributes_to	pathway	0.85
neuronal excitability	inhibits	phenotype	0.85
Cerebellar Neurodegeneration	contributes_to	phenotype	0.85
Parkinson's Disease	contributes_to	disease	0.85
APOE	upregulates	gene	0.85
TREM2	upregulates	gene	0.85
SOD1-G93A	associated_with	gene	0.85
CXCL10 production	causes (microglial activation orchestrates CXCL10-mediated)	protein	0.85
Parkinson'S Disease	contributes_to	disease	0.85
Tau Pathology	contributes_to	phenotype	0.80
Ischemic Stroke	contributes_to	disease	0.80
Tau Pathology	modulates	phenotype	0.80
Glucose Metabolic Alterations	associated_with	process	0.80
Dopaminergic Neurons	causes	cell_type	0.80
Neuronal Loss	mediates	process	0.80
neuronal damage	contributes_to	phenotype	0.80
Behavioral Impairments	contributes_to	phenotype	0.80
Neuroinflammation	mediates	process	0.80
MITOCHONDRIAL DYSFUNCTION	exacerbates	phenotype	0.70
ASTROCYTE	inhibits	cell_type	0.70
TNF	causes	gene	0.70
Aβ plaque deposition	activates	process	0.70
sepsis-associated encephalopathy	associated_with	disease	0.70
sepsis-associated encephalopathy	regulates	disease	0.70
DEPRESSION	regulates	disease	0.70
CYTOKINES	causes	phenotype	0.70
TNF	phosphorylates	gene	0.70
neuroinflammation	activates	process	0.70
Alzheimer's disease	associated_with	disease	0.70
amyloid-beta	activates	protein	0.70
INTERNEURONS	causes	cell_type	0.70
OLIGODENDROCYTE	activates	cell_type	0.70
OLIGODENDROCYTE	stabilizes	cell_type	0.70
ALS	treats	disease	0.70
TEMPORAL LOBE	exacerbates	brain_region	0.70
STROKE	causes	disease	0.70
Neuroinflammation	activates	process	0.70
WHITE MATTER	treats	brain_region	0.70

Incoming (285)

Source	Relation	Type	Str
NFE2L2	regulates	gene	0.95
C9orf72 Hexanucleotide Repeat Expansion	inhibits	mechanism	0.95
CKLF	causes	protein	0.95
Mitophagy	involved_in	process	0.95
GAL3	promotes	protein	0.95
sTREM2	biomarker_for	biomarker	0.93
NRF2	regulates	gene	0.92
LAG3	mediates	protein	0.92
REV-ERBα	regulates	protein	0.92
Amyloid-beta aggregation	associated_with	process	0.90
TREM2/DAP12	regulates	protein	0.90
Aβ	causes	protein	0.90
Microbiota-Gut-Brain Axis	modulates	pathway	0.90
APOE	activates	protein	0.90
AGER	activates	receptor	0.90
Gastrodin	inhibits	compound	0.90
Lipopolysaccharide	activates	compound	0.90
LDLR overexpression	suppresses	process	0.90
CX3CL1-CX3CR1 signaling	regulates	pathway	0.90
CX3CL1	modulates	protein	0.90
HMGB1	activates	protein	0.90
CKLF1	causes	gene	0.90
CKLF	causes	protein	0.90
HSYA	suppresses	compound	0.90
NLRP3/JAK1/STAT3	mediates	pathway	0.90
Lgals3	drives	protein	0.90
HV1	involved_in	gene	0.90
APOE ε2	inhibits	protein	0.90
defective mitophagy	causes	phenotype	0.90
Alpha-Synuclein Aggregates	causes	compound	0.90
TREM2	mediates	protein	0.89
Amyloid-Β Deposition	correlates_with	phenotype	0.87
Microbial-derived Metabolites	regulates	compound	0.85
ANXA1	regulates	protein	0.85
HVCN1	involved_in	gene	0.85
KCNA3	contributes_to	protein	0.85
SNCA	activates	protein	0.85
Berbamine hydrochloride	inhibits	compound	0.85
TREM2	involved_in	gene	0.85
KV1.3	contributes_to	protein	0.85
CD33	regulates	gene	0.85
AIF1	biomarker_for	gene	0.85
CSF1R	modulates	gene	0.85
TREM2	biomarker_for	protein	0.85
Complement C3	activates	protein	0.85
HV1	contributes_to	gene	0.85
KV1.3	modulates	gene	0.85
C3A RECEPTOR	activates	receptor	0.85
APOE ε2 Gene Therapy	inhibits	drug	0.85
Chi3L1 Deletion	promotes	phenotype	0.85

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
GluN2B-Mediated Microglial Activation and Tau Propagation	0.555	neuroscience	Circuit-level neural dynamics in neurode
Temporal NLRP3 Inhibition During SPP1-Driven Microglial Acti	0.551	neuroinflammation	What molecular mechanisms mediate SPP1-i

Mentioning Analyses (6)

Scientific analyses that reference this entity

Does Alectinib truly bind C1q directly with high affinity, or is this an experim

molecular biology | 2026-04-21 | 1 hypotheses Top: 0.582

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

neurodegeneration | 2026-04-16 | 0 hypotheses

Multi-modal Biomarker Panel Design for Early AD Detection

neurodegeneration | 2026-04-16 | 0 hypotheses

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

neurodegeneration | 2026-04-08 | 0 hypotheses

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

neuroscience | 2026-04-04 | 7 hypotheses Top: 0.680

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (8)

Multi-agent debates referencing this entity

Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma

closed · Rounds: 4 · Score: 0.76 · 2026-04-22

Can a multi-modal biomarker panel combining plasma proteins, neuroimaging featur

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Which clinical, genetic, and biomarker features are independent prognostic marke

closed · Rounds: 4 · Score: 0.60 · 2026-04-21

The fundamental premise remains unvalidated despite extensive mechanistic specul

closed · Rounds: 4 · Score: 0.50 · 2026-04-21

Is a 3-marker prognostic index clinically actionable for MCI patients, or does t

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Should clinical practice adopt multi-modal biomarker panels now, or wait for sin

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

closed · Rounds: 4 · Score: 0.94 · 2026-04-10

What gene expression changes in the aging mouse brain predict neurodegenerative

closed · Rounds: 4 · Score: 0.95 · 2026-04-03

MICROGLIAL ACTIVATION

Understanding Entity Pages

Pathway Diagram

Outgoing (132)

Incoming (285)

Targeting Hypotheses (2)

Mentioning Analyses (6)

Does Alectinib truly bind C1q directly with high affinity, or is this an experim

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

Multi-modal Biomarker Panel Design for Early AD Detection

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Experiments (0)

Related Papers (0)

Debates (8)

Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma

Can a multi-modal biomarker panel combining plasma proteins, neuroimaging featur

Which clinical, genetic, and biomarker features are independent prognostic marke

The fundamental premise remains unvalidated despite extensive mechanistic specul

Is a 3-marker prognostic index clinically actionable for MCI patients, or does t

Should clinical practice adopt multi-modal biomarker panels now, or wait for sin

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

What gene expression changes in the aging mouse brain predict neurodegenerative